FIP1L1/PDGFRά synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia hypereosinophilic syndrome

Blood

Volumn 112, Issue 6, 2008, Pages 2500-2507

  Yamada, Yoshiyuki ^a   Sanchez Aguilera, Abel ^a   Brandt, Eric B ^a   McBride, Melissa ^a   Al Moamen, Nabeel J H ^b   Finkelman, Fred D ^b   Williams, David A ^c   Cancelas, Jose A ^a,b   Rothenberg, Marc E ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR RECEPTOR; STAT5 PROTEIN; STEM CELL FACTOR; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; FIP1L1 PROTEIN, HUMAN; HYBRID PROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; EOSINOPHILIC LEUKEMIA; FEMALE; HYPEREOSINOPHILIC SYNDROME; MASTOCYTOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC MASTOCYTOSIS; ANIMAL; CELL DIFFERENTIATION; CELL MOTION; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HYPEREOSINOPHILIC SYNDROME; MASTOCYTOSIS, SYSTEMIC; MICE; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECOMBINANT FUSION PROTEINS; STEM CELL FACTOR;

EID: 55249083813     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-126268     Document Type: Article

References (42)

1. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol. 2004;77: 82-85.
2. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007:37:435-453.
3. Zappulla JR Dubreuil P, Desbois S, et al. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med. 2005;202:1635-1641.
4. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660-4666.
5. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102:3093-3096.
6. Cools J, DeAngelo DJ, Gotlib J, et al. Atyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
7. Patnaik MM, Rindos M, Kouides PA, Tefferi A, Pardanani A. Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med. 2007;131:784-791.
8. Robyn J, Lemery S, McCoy JP, et al. Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol. 2006;132:286-292.
9. Tefferi A, Lasho TL, Brockman SR, Elliott MA, Dispenzieri A, Pardanani A. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophil. Haematologica. 2004;89:871-873.
10. Marie I, Robyn J, Metcalfe DD, etal. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol. 2007;120:680-687.
11. Yamada Y, Rothenberg ME, Lee AW, etal. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL) disease. Blood. 2006;107:4071-4079.
12. Yamada Y, Rothenberg ME, Cancelas JA. Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia. Transl Oncogenom. 2006;2:53-63.
13. Xiang Z. Kreisel F, Cain J. Colson A, Tomasson MH. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol. 2007;27:267-282.
14. MishraA, Hogan SP, Brandt EB, Rothenberg ME. IL-5 promotes eosinophil trafficking to the esophagus. J Immunol. 2002;168:2464-2469.
15. Hawley RG, Covarrubias L, Hawley T, Mintz B. Handicapped retroviral vectors efficiently transduce foreign genes into hematopoietic stem cells. Proc Natl Acad Sci U S A. 1987;84:2406-2410.
16. Cools J, Stover EH, Boulton CL, etal. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell. 2003;3:459-469.
17. Li S, Gillessen S, Tomasson MH, Dranoff G, Gilliland DG, Van Etten RA. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia myeloproliferative disease in mice by BCR/ABL. Blood. 2001;97:1442-1450.
18. Williams DA, Tao W, Yang F et al. Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. Blood. 2000:96: 1646-1654.
19. Brandt EB, Strait RT, Hershko D, et al. Mast cells are required for experimental oral allergen-induced diarrhea. J Clin Invest. 2003;112:1666-1677.
20. Friend DS, Ghildyal N, Austen KF, Gurish MF, Matsumoto R. Stevens RL. Mast cells that reside at different locations in the jejunum of mice infected with Trichinella spiralis exhibit sequential changes in their granule ultrastructure and chymase phenotype. J Cell Biol. 1996;135:279-290.
21. Sheehan D, Hrapchak B. Theory and Practice of Histotechnology. 2nd ed. Columbus, Ohio: Battelle Press; 1980.
22. Cancelas JA, Lee AW, Prabhakar R, Stringer KF, Zheng Y, Williams DA. Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. Nat Med. 2005;11:886-891.
23. Minns LA, Menard LC, Foureau DM, et al. TLR9 is required for the gut-associated lymphoid tissue response following oral infection of Toxoplasma gondii. J Immunol. 2006;176:7589-7597.
24. Gu Y, Byrne MC, Paranavitana NC, et al. Rac2, a hematopoiesis-specific Rho GTPase, specifically regulates mast cell protease gene expression in bone marrow-derived mast cells. Mol Cell Biol. 2002;22:7645-7657.
25. Yang FC, Kapur R, King AJ, et al. Rac2 stimulates Akt activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells. Immunity. 2000;12:557-568.
26. Gurish MF, Boyce JA. Mast cells: ontogeny, homing, and recruitment of a unique innate effector cell. J Allergy Clin Immunol. 2006;117:1285-1291.
27. Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139:351-362.
28. Dahlen DD, Lin NL, Liu YC, Broudy VC. Soluble Kit receptor blocks stem cell factor bioactivity in vitro. Leuk Res. 2001;25:413-421.
29. CzechowiczA, Kraft D, Weissman IL, Bhattacharya D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science. 2007;318:1296-1299.
30. Crowell JA, Steele VE, Fay JR. Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther. 2007;6:2139-2148.
31. Buitenhuis M, Verhagen LP, Cools J, Coffer PJ. Molecular mechanisms underlying FIP1L1-PDG-FRA-mediated myeloproliferation. Cancer Res. 2007;67:3759-3766.
32. Valent P, Akin C, Metcalfe DD. FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis. Eur J Clin Invest. 2007;37:153-154.
33. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104:3038-3045.
34. Pardanani A, Akin C, Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol. 2006; 19:595-615.
35. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol. 2007;138:12-30.
36. Heinrich MC. Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-710.
37. Lorentz A, Bischoff SC. Regulation of human intestinal mast cells by stem cell factor and IL-4. Immunol Rev. 2001;179:57-60.
38. Rennick D, Hunte B, Holland G, Thompson-Snipes L. Cofactors are essential for stem cell factor-dependent growth and maturation of mast cell progenitors: comparative effects of interleukin-3 (IL-3), IL-4, IL-10, and fibroblasts. Blood. 1995;85:57-65.
39. Lantz CS, Huff TF Differential responsiveness of purified mouse c-kit+ mast cells and their progenitors to IL-3 and stem cell factor. J Immunol. 1995;155:4024-4029.
40. Stover EH, Chen J, Folens C, et al. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci U S A. 2006;103:8078-8083.
41. Baselga J, Arribas J. Treating cancer's kinase 'addiction.' Nat Med. 2004;10:786-787.
42. Arbiser JL. Why targeted therapy hasn't worked in advanced cancer. J Clin Invest. 2007;117: 2762-2765.